Veterinary Vaccines Market

Industry Outlook

Immunization of livestock has been carried out worldwide for centuries and is also accepted as a cost-effective measure for controlling infections. Until recently, vaccines were either live attenuated or inactivated organisms formulated with an oil-based adjuvant; however, these methods and formulations were not very effective. The introduction of gene delivery systems has rendered the development of novel therapeutic and prophylactic vaccines possible. The identification of vaccine candidates in genomic sequences proved to be a revolutionary approach, where antibodies were assumed to easily access the cell surface. Reverse vaccination makes use of different bioinformatics algorithms for predicting antigen localization and is now successfully applied for immunization against a range of veterinary diseases.

The global veterinary vaccines market is being driven by the increasing prevalence of animal diseases and the increasing demand for companion animals. Vaccination protects millions of animals from diseases and fatalities. As the field of veterinary medicine advances, disease prevention has become a priority. Therefore, one of the best measures for disease prevention is enhancing animal immunity. Vaccination programs for farm animals depend on management systems, farm location, and the nature of the herd or flock. Veterinary vaccines continue to play a major role in protecting animal health and, consequently, ensuring public health and reducing the use of antibiotics in animals. Some prominent veterinary vaccines include the rinderpest and rabies vaccines. Rabies vaccines for domestic and wild animals have nearly eradicated the risk of human rabies. The Global Rinderpest Eradication Program, which involved trade restrictions, surveillance, and vaccination, has led to a significant reduction in incidence, making it the second disease after smallpox to be eradicated worldwide. Prominent examples of new technologies in animal vaccines that are licensed include DNA vaccines, virus-like particle vaccines, and recombinant, modified live virus vaccines. Animal vaccines also make use of novel adjuvants that are not yet incorporated into human use. Furthermore, animal vaccines can also be developed and commercialized more quickly than human vaccines. Furthermore, for animal vaccines to effectively safeguard animal health, they should be widely used and, therefore, affordable. Regulatory processes, therefore, need to ensure product safety and efficacy without increasing licensing and production costs.

Market Synopsis

live-attenuated vaccines to dominate the global market

Live-attenuated vaccines based on genetic mutation are the most dominant segment in the global market. Better long-term immunity, the inclusion of both cellular and humoral immunity, efficacy, and targeting, and ease of administration are the key factors that support the dominance of this segment. However, the fact that live strains are not very effective and require refrigerated storage may restrain the market growth of this segment. Live attenuated vaccines are created in two ways: by combining attenuated animal or human virus strains or by serially passing initially pathogenic viruses or bacteria and selecting less pathogenic strains that may induce protective immunity. These vaccines are believed to augment the immunologic response, similar to the response resulting from a natural infection. The advantage of a live-attenuated vaccine is the replication of organisms and antigen processing that mimics a natural infection, both cell-mediated and humoral. Such conferred immunity may also be long-lasting or even lifelong.

High demand for pets and companion animals, as well as increased healthcare spending in this demographic, will drive market growth.

At present, livestock, particularly porcine breeds, occupy the largest share in the consumption of veterinary vaccines. The increase in global consumption of livestock through meat and dairy products is the prime factor driving the dominance of this segment. As the global population increases, the world faces more mouths to feed with nutritional products, which has urged the food industry to enhance the production of farm animals. The purpose of using vaccines for livestock is to increase productivity and profitability for producers. The use of vaccination for zoonotic diseases in livestock is expected to eliminate or reduce the risk of transmission of these diseases to consumers while also protecting industry animals. The large-scale use of nontherapeutic antibiotics in livestock has resulted in the emergence of antibiotic-resistant bacteria. Such issues have increased the use of vaccines in livestock animals. On the other hand, the growth rate of pet and companion animal vaccines is expected to surpass the overall market benchmark during the forecast period. In companion animal vaccines, canine vaccines hold the most prominent share and will assist in the development of the market through the forecast period. Increased adoption of pet animals in the general population, heightened uptake among disabled patients, and increasing spending on scheduled well-being measures for such animals are the key factors facilitating the swift growth of this segment.

Vaccines for Viral and Bacterial Infections Spearhead the Global Market

At present, there are no broad-spectrum antiviral medications available for veterinary purposes. Therefore, employment of a hygienic environment, limiting exposure, and vaccination are the only methods for the prevention of viral infections in animals. RNA viruses are very variable, and many viral infections occur from viruses with different serotypes. Therefore, several of the currently available viral vaccines are not able to combat infections caused by the prevailing strains. Several conventional inactivated and live-attenuated vaccines are being produced by veterinary health companies and have been on the market for many decades as a part of the routine vaccination protocol. Furthermore, many subunits and rationally designed vaccines are being introduced into the market. Several prophylactic live, attenuated, or inactivated bacterial vaccines are available on the market. For a majority of attenuated bacterial strains, the form of attenuation is unknown, and since there is no proven track record, researchers have done little to characterize the underlying genetics. However, in some cases, the old live strains are not very protective, and perpetual research is being conducted to develop new and improved vaccine strategies against diseases such as paratuberculosis, brucellosis, and bovine tuberculosis.

Because of increased awareness and a favorable business environment, the United States leads the global veterinary vaccines market.

Geographically, North America, particularly the United States, holds the largest revenue share in the global veterinary vaccine market. Enhanced and widespread vaccination programs, increasing adoption of companion animals, and greater awareness are the key factors supporting the dominance of this regional market. Furthermore, acceptance of advanced vaccine products such as DNA and recombinant vaccines is also significantly high in North America. Asia Pacific shall advance at the fastest growth rate during the forecast period from 2018 to 2026. The ownership of companion animals is perpetually growing in the region due to increasing disposable incomes. Livestock farming in Asia-Pacific is also perpetually advancing in terms of animal healthcare and technologies. Countries such as India, China, Brazil, and South Africa will be the fastest-progressing country-level markets.

Periods of History and Forecast

This research report presents the analysis of each considered segment for the period from 2016 to 2026, using 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report presents a market analysis of veterinary vaccines in terms of qualitative and quantitative information for the forecast period of 2016–2026. The study includes qualitative information such as market analysis for each mentioned segment, market drivers, challenges, and opportunities relevant to the industry. The global veterinary vaccines market is segmented in terms of vaccine types, wound types, disease types, and geography.

The report also presents insights into the competitive landscape prevalent in the global veterinary vaccines market, along with a profile of key companies operating in the industry. Such major market players profiled in this report include Merck Animal Health, Zoetis, Inc., Merial (Boehringer Ingelheim International GmbH), Elanco Animal Health, Bayer Animal Health, Novartis Animal Health, Virbac Group, Ceva Santé Animale S.A., and Biovac.

Key questions are answered in this report.

• What is the market size and forecast for the period from 2016 to 2026?
• What is the compounded annual growth rate of the global veterinary vaccine market?
• How does the livestock animal segment hold dominance in the global market?
• What is the market potential for DNA and recombinant vaccines?
• What are the drivers, challenges, and opportunities relevant to the industry?
• How will the Asia-Pacific region progress on the global front?
• What is the competitive landscape in the global veterinary vaccines market, and which companies hold key positions in the global market?
• What is the situation of emerging markets in the Middle East, Africa, and Latin America through the forecast period?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions
1.5. Market Segmentation

Chapter 2. Executive Summary
2.1. Global VV Market Portraiture
2.2. Global VV Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global VV Market, by Animal Type, 2017 (US$ Mn)
2.4. Global VV Market, by Disease Type, 2017 (US$ Mn)
2.5. Global VV Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global VV Market: Dynamics and Future Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global VV Market, by Key Players, 2017

Chapter 4. Global VV Market, by Vaccine Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Live-attenuated
4.3. Inactivated
4.4. Toxoids
4.5. Recombinant subunit
4.6. RNA/DNA-based
4.7. Vectored-based

Chapter 5. Global VV Market, by Animal Type, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Livestock
5.2.1. Bovine
5.2.2. Poultry
5.2.3. Porcine
5.2.4. Others (Sheep/goats, Fish)
5.3. Pet Animals
5.3.1. Feline
5.3.2. Canine
5.3.3. Equine
5.3.4. Others (Rodents, Birds etc.)

Chapter 6. Global VV Market, by Disease Type, 2016-2026 (US$ Mn)
6.1. Overview
6.2. Viral Diseases
6.3. Bacterial Diseases
6.4. Parasitic Diseases
6.5. Non-infectious Diseases
6.6. Fertility

Chapter 7. Global VV Market, by Geography, 2016 – 2026 (US$ Mn)
7.1. Overview
7.1.1. North America VV Market, 2016-2026 (US$ Mn)
7.1.2. North America VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
7.1.3. North America VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
7.1.4. North America VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.1.5. North America VV Market, by Country, 2016 – 2026 (US$ Mn)
7.1.5.1. U.S.
7.1.5.2. Canada
7.2. Europe VV Market, 2016 – 2026 (US$ Mn)
7.2.1. Europe VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
7.2.2. Europe VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
7.2.3. Europe VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.2.4. Europe VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.2.4.1. U.K.
7.2.4.2. Germany
7.2.4.3. Rest of Europe
7.3. Asia Pacific VV Market, 2016 – 2026 (US$ Mn)
7.3.1. Asia Pacific VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
7.3.2. Asia Pacific VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
7.3.3. Asia Pacific VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.3.4. Asia Pacific VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.3.4.1. China
7.3.4.2. Japan
7.3.4.3. Rest of Asia Pacific
7.4. Latin America VV Market, 2016 – 2026 (US$ Mn)
7.4.1. Latin America VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
7.4.2. Latin America VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
7.4.3. Latin America VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.4.4. Latin America VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.4.4.1. Brazil
7.4.4.2. Mexico
7.4.4.3. Rest of Latin America
7.5. Middle East & Africa VV Market, 2016 – 2026 (US$ Mn)
7.5.1. Middle East & Africa VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
7.5.2. Middle East & Africa VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
7.5.3. Middle East & Africa VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
7.5.4. Middle East & Africa VV Market, by Region, 2016 – 2026 (US$ Mn)
7.5.4.1. GCC
7.5.4.2. Rest of Middle East & Africa

Chapter 8. Company Profiles
8.1. Merck Animal Health
8.1.1. Business Description
8.1.2. Financial Information (Subject to Data Availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Zoetis, Inc.
8.3. Merial (Boehringer Ingelheim International GmbH)
8.4. Elanco Animal Health
8.5. Bayer Animal Health
8.6. Novartis Animal Health
8.7. Virbac Group
8.8. Ceva Santé Animale S.A.
8.9. Biovac

List of Figures

FIG 1. VV Market: Research Methodology
FIG 2. Deep Brain Stimulation Devices: Market Segmentation
FIG 3. Global VV Market, by Vaccine Type, 2017 (US$ Mn)
FIG 4. Global VV Market, by Animal Type, 2017 (US$ Mn)
FIG 5. Global VV Market, by Disease Type, 2017 (US$ Mn)
FIG 6. Global VV Market, by Geography, 2017 (US$ Mn)
FIG 7. Attractive Investment Proposition, by Geography, 2017
FIG 8. Competitive Analysis: Global VV Market, by Key Players, 2017
FIG 9. Global Live-attenuated VV Market, 2016-2026(US$ Mn)
FIG 10. Global Inactivated VV Market, 2016-2026 (US$ Mn)
FIG 11. Global Toxoids VV Market, 2016-2026 (US$ Mn)
FIG 12. Global Low-tech VV Market, 2016-2026 (US$ Mn)
FIG 13. Global Recombinant subunit VV Market, 2016-2026 (US$ Mn)
FIG 14. Global RNA/DNA-based VV Market, 2016-2026 (US$ Mn)
FIG 15. Global Vectored-based VV Market, 2016-2026 (US$ Mn)
FIG 16. Global Bovine VV Market, 2016-2026 (US$ Mn)
FIG 17. Global Poultry VV Market, 2016-2026 (US$ Mn)
FIG 18. Global Porcine VV Market, 2016-2026 (US$ Mn)
FIG 19. Global VV Market for Other Livestock, 2016-2026 (US$ Mn)
FIG 20. Global Feline VV Market, 2016-2026 (US$ Mn)
FIG 21. Global Canine VV Market, 2016-2026 (US$ Mn)
FIG 22. Global Equine VV Market, 2016-2026 (US$ Mn)
FIG 23. Global VV Market for Other Pet Animals, 2016-2026 (US$ Mn)
FIG 24. Global VV Market for Viral Diseases, 2016-2026 (US$ Mn)
FIG 25. Global VV Market for Bacterial Diseases, 2016-2026 (US$ Mn)
FIG 26. Global VV Market for Parasitic Diseases, 2016-2026 (US$ Mn)
FIG 27. Global Veterinary Vaccines (VV) Market for Non-infectious Diseases, 2016-2026 (US$ Mn)
FIG 28. Global VV Market for Fertility, 2016-2026 (US$ Mn)
FIG 29. U.S. VV Market, 2016-2026 (US$ Mn)
FIG 30. Canada VV Market, 2016-2026 (US$ Mn)
FIG 31. U.K. VV Market, 2016-2026 (US$ Mn)
FIG 32. Germany VV Market, 2016-2026 (US$ Mn)
FIG 33. Rest of Europe VV Market, 2016-2026 (US$ Mn)
FIG 34. China VV Market, 2016-2026 (US$ Mn)
FIG 35. Japan VV Market, 2016-2026 (US$ Mn)
FIG 36. Rest of Asia Pacific VV Market, 2016-2026 (US$ Mn)
FIG 37. Brazil VV Market, 2016-2026 (US$ Mn)
FIG 38. Mexico VV Market, 2016-2026 (US$ Mn)
FIG 39. Rest of Latin America VV Market, 2016-2026 (US$ Mn)
FIG 40. GCC VV Market, 2016-2026 (US$ Mn)
FIG 41. Rest of Middle East and Africa VV Market, 2016-2026 (US$ Mn)

List of Tables

TABLE 1 Global Veterinary Vaccines (VV) Market Portraiture
TABLE 2 Global VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global VV Market for Livestock Animals, by Type, 2016 – 2026 (US$ Mn)
TABLE 5 Global VV Market for Pet Animals, by Type, 2016 – 2026 (US$ Mn)
TABLE 6 Global VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 7 Global VV Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 9 North America VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 10 North America VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 11 North America VV Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 12 Europe VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 13 Europe VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 14 Europe VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 15 Europe VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 18 Asia Pacific VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 19 Asia Pacific VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Latin America VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 21 Latin America VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 22 Latin America VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 23 Latin America VV Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 24 Middle East and Africa VV Market, by Vaccine Type, 2016 – 2026 (US$ Mn)
TABLE 25 Middle East and Africa VV Market, by Animal Type, 2016 – 2026 (US$ Mn)
TABLE 26 Middle East and Africa VV Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 27 Middle East and Africa VV Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 28 Merck Animal Health: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Zoetis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Merial (Boehringer Ingelheim International GmbH): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Elanco Animal Health: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Bayer Animal Health: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 Novartis Animal Health: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 34 Virbac Group: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 35 Ceva Santé Animale S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 36 Biovac: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)